Humoral and cell-mediated immune response in patients with malignant melanoma.I. In vitro lymphocyte reactivity to pha and antigens following immunization

Gast, G. C. De; Koops, H. Schraffordt; Huiges, H. A.; Oldhoff, J; Nieweg, H. O.

doi:10.1002/1097-0142(197510)36:4<1289::aid-cncr2820360415>3.0.co;2-p

Cited by 16 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Golub [9] studied lymphocyte transformation to PHA, pokeweed mitogen (PWM) and ConA in 29 melanoma patients, and found that these patients, as a whole, had decreased responses compared with healthy controls. In a more extensive study assessing blastogenesis to PHA and three antigens (diphtheria, tetanus toxoid, hemocyanin) in 61 melanoma patients, DeGast noted that patients with progressive visceral disease had significantly decreased transformation compared with normal controls as well as patients with minimal disease [5]. In a more extensive study assessing blastogenesis to PHA and three antigens (diphtheria, tetanus toxoid, hemocyanin) in 61 melanoma patients, DeGast noted that patients with progressive visceral disease had significantly decreased transformation compared with normal controls as well as patients with minimal disease [5].…”

Section: Discussionmentioning

confidence: 99%

Adherent indomethacin-sensitive suppressor cells in malignant melanoma

Murray

Springle

Ishmael³

et al. 1981

Cancer Immunol Immunother

View full text Add to dashboard Cite

Twenty-five patients with malignant melanoma were studied to determine the mechanisms underlying decreased cellular immunity in this disease. Sixteen patients were examined following surgical resections of tumor, and nine patients had evidence of metastases. Patients with metastatic disease (group II) had decreased lymphocyte transformation to concanavalin A (48,255 +_ 30,074) compared with controls (83,550 + 41,277) and patients free of disease (group I) 110,231 +_ 59,990) (P > 0.01). Rigorous depletion of monocytes by adherent techniques resulted in an improvement in blastogenesis in seven of nine group H patients, whereas controls and group I patients had marked decreases in reactivity. Indomethacin also improved lymphocyte reactivity; a mean of 166.4% was recorded in five metastatic disease patients studied, as against a mean of 2% in group I and 9.65% in controls. In seven patients followed serially the presence of adherent suppressor cells tended to correlate with progressive disease, shorter survival, and decreased skin test reactivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherent indomethacin-sensitive suppressor cells in malignant melanoma

Murray

Springle

Ishmael³

et al. 1981

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up

Bernengo

Lisa

Meregalli

et al. 1983

Cancer

View full text Add to dashboard Cite

Serial immunologic tests (active E‐rosettes = T‐Et; total E‐rosettes = T‐Et; total lymphocytes and null cells) were performed every 3 months for 5 years on 113 melanoma patients. A significant reduction in absolute T‐Ea, T‐Et, null cells, and total lymphocytes was noted in the patients who died, by comparison with those who are still alive. The latter presented a significant reduction in absolute T‐Et only, plus a significant increase in null cells when compared with normals. The 38 patients without metastases, at the end of the study, presented a reduction in T‐Et and an increase in null cells compared with the normals, while the 75 patients with metastases presented a reduction in T‐Et, null cells and total lymphocytes when compared with the patients without metastases and a reduction in T‐Ea, T‐Et, and total lymphocytes when compared with the normals. Null cells show a linear decrease in patients who died and a linear increase in those who survived. A total of 80.2% of patients with a fall in T‐Et displayed metastases usually within 2 to 10 months (mean, 6.8). Patients with normal T‐Ea, T‐Et, and total lymphocyte values showed a significant prolonged survival when compared to those with lower values. In addition, survival seemed to be always a function of immunologic test values, irrespective of the tumor site.

show abstract

Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma

Elsässer‐Beile

Kleist

Stähle

et al. 1993

Cancer

View full text Add to dashboard Cite

For the determination of cellular immunity status, mitogen‐induced lymphocyte proliferation tests are used, along with measurements of cytokine secretion. The authors have established a test system with whole blood cell cultures in which they measured the following cytokines: alpha‐interleukin‐1 (α‐IL‐1), interleukin‐2 (IL‐2), gamma‐interferon (τ‐IFN), and alpha‐tumor necrosis factor (α‐TNF) in the supernatants by enzymoimmunologic methods. With this system, the authors tested blood samples of 72 patients with malignant melanoma, 38 patients with basal cell carcinoma, and 315 healthy control subjects. In the blood cell cultures of the patients with melanoma, significantly lower values of the lymphokines τ‐IFN and IL‐2 were found, compared with those of the control subjects, and the levels of the monokines α‐IL‐1 and α‐TNF were reduced. τ‐IFN values correlated with different clinical stages. In contrast, the patients with basal cell carcinoma had equal values for all four cytokines as an age‐matched control group. Cancer 1993; 71:231‐6.

show abstract

Humoral and cell-mediated immune response in patients with malignant melanoma.I. In vitro lymphocyte reactivity to pha and antigens following immunization

Cited by 16 publications

References 14 publications

Adherent indomethacin-sensitive suppressor cells in malignant melanoma

Adherent indomethacin-sensitive suppressor cells in malignant melanoma

The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up

Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma

Contact Info

Product

Resources

About